Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Payables (2016 - 2025)

Guided Therapeutics' Payables history spans 16 years, with the latest figure at $2.5 million for Q3 2025.

  • For Q3 2025, Payables rose 8.55% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, up 8.55%, while the annual FY2024 figure was $2.2 million, 8.93% up from the prior year.
  • Payables for Q3 2025 was $2.5 million at Guided Therapeutics, up from $2.3 million in the prior quarter.
  • Across five years, Payables topped out at $2.5 million in Q3 2025 and bottomed at $51770.0 in Q1 2023.
  • The 5-year median for Payables is $2.2 million (2024), against an average of $1.8 million.
  • The largest annual shift saw Payables crashed 95.12% in 2022 before it soared 3662.8% in 2024.
  • A 5-year view of Payables shows it stood at $2.5 million in 2021, then dropped by 11.11% to $2.2 million in 2022, then fell by 8.59% to $2.0 million in 2023, then rose by 8.93% to $2.2 million in 2024, then increased by 13.17% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Payables are $2.5 million (Q3 2025), $2.3 million (Q2 2025), and $2.2 million (Q1 2025).